XPhyto Therapeutics (CSE: XPHY – OTCQB: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to share details of the company’s GMP mescaline synthesis program is on schedule and they have completed their initial production batches.
Rogers telling Proactive this industrial-scale manufacture of pharmaceutical-grade psychedelic compounds, including mescaline and psilocybin, is the next step for providing a foundation for its drug formulation and clinical validation work.